Drugs / ODM-204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02344017 | Feb 2015 → Jan 2019 | prostate cancer | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02344017 ↗ |
| Modality | Small molecule | — CHEMBL6068517 ↗ |
| Route | Oral | “co-administered with prednisone, orally daily” NCT02344017 ↗ |